NEW YORK, April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit-s ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=144420&from=3 CLASS PERIOD: Octobe ...

NEW YORK  , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/actinium-law ...

NEW YORK, April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=143830&from=4 CLASS PERIOD: October 31, 2 ...

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE:ATNM) securities during the period from October 31, 2022, through August 2, 2024 (“the Class Period”). Investors have until May 27, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsu ...

诉讼基本信息 - 律师事务所Levi & Korsinsky, LLP通知Actinium Pharmaceuticals, Inc (NYSE: ATNM)的投资者有关一项证券集体诉讼 [1] - 该诉讼旨在为在2022年10月31日至2024年8月2日期间因涉嫌证券欺诈而遭受损失的投资者挽回损失 [1] - 受影响投资者可在2025年5月27日前请求法院指定其为首席原告 [3] 诉讼指控内容 - 指控公司被告作出了虚假陈述和/或隐瞒了以下事实：公司SIERRA三期试验的数据不太可能满足FDA关于接受和批准其靶向放疗药物Iomab-B的生物制品许可申请(BLA)的指导原则 [2] - 指控公司为减轻SIERRA试验不佳的总生存期(OS)数据而向FDA提供的额外分析（包括长期随访数据）不太可能满足FDA关于接受和批准Iomab-B BLA的指导原则 [2] - 指控因此FDA很可能拒绝审查Iomab-B的BLA，或者即使审查，当前形式的申请也不太可能获得批准 [2] - 指控基于以上原因，被告关于公司业务、运营和前景的正面陈述存在重大误导性和/或缺乏合理依据 [2]

NEW YORK, April 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit-s ...

文章核心观点 Gross Law Firm通知Actinium Pharmaceuticals股东可联系该律所参与集体诉讼，指控被告在特定期间发布虚假误导声明或未披露关键信息致股价虚高，鼓励股东登记参与，无成本义务，申请首席原告截止日期为2025年5月27日 [1][2][3] 分组1：集体诉讼通知 - 律所鼓励在特定期间购买Actinium Pharmaceuticals股票的股东联系律所，申请首席原告非参与赔偿必要条件 [1] 分组2：联系方式与诉讼期间 - 联系网址为https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=143346&from=4 [2][3] - 集体诉讼期间为2022年10月31日至2024年8月2日 [2] 分组3：指控内容 - 被告在集体诉讼期间发布虚假误导声明或未披露信息，包括公司3期Sierra试验数据、额外分析不太可能满足FDA对Iomab - B BLA的接受和批准指南，FDA可能拒绝审查或不批准该申请，被告对公司业务等积极表述具误导性或缺乏合理依据 [2] 分组4：截止日期与后续步骤 - 申请首席原告截止日期为2025年5月27日，股东应尽快登记 [3] - 登记后将被纳入投资组合监控软件以获取案件状态更新，参与案件无成本和义务 [3] 分组5：律所介绍 - Gross Law Firm是全国知名集体诉讼律所，使命是保护因欺诈等受损投资者权益，确保公司合规经营，为因公司虚假信息致损投资者寻求赔偿 [4] 分组6：律所联系方式 - 律所地址为纽约西38街15号12层，邮编10018 [5] - 邮箱为[email protected]，电话为(646) 453 - 8903 [5]

Solaris Energy Infrastructure公司集体诉讼 - 诉讼指控公司在2024年7月9日至2025年3月17日期间未披露Mobile Energy Rentals LLC（MER）在移动涡轮租赁领域几乎无企业历史 [2] - 指控MER缺乏多元化收益流且共同所有者涉及涡轮欺诈前科导致Solaris夸大收购商业前景 [2] - 公司被指通过不当折旧涡轮资产虚增盈利指标 [2] Actinium Pharmaceuticals公司集体诉讼 - 公司在2022年10月31日至2024年8月2日期间被指控虚假宣称Iomab-B的BLA申请数据符合FDA指南实际需追加临床试验 [3] - 市场知悉真相后投资者遭受损失 [3] Bakkt Holdings公司集体诉讼 - 2024年3月25日至2025年3月17日期间公司被指隐瞒加密服务收入过度依赖Webull单一合约 [4] - 指控公司误导关键客户关系稳定性表述 [4] Cerevel Therapeutics公司集体诉讼 - 2023年10月11日至2024年8月1日期间公司被控未披露AbbVie有意以每股45美元收购（远高于发行价22.81美元）导致股价人为压低 [6] - 控股股东Bain被指利用非公开信息以低价购股并在并购后获利超1.2亿美元 [6] - 2024年1月18日代理声明被控误导AbbVie收购意向的真实性质与时间 [7]